These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 28895030)

  • 21. Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.
    Thompson PL; Davis TME
    Clin Ther; 2017 May; 39(5):1012-1025. PubMed ID: 27863704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Diabetes Mellitus Type 2: Recent Publications and New Drugs].
    Elbelt U
    Dtsch Med Wochenschr; 2018 Jun; 143(11):772-776. PubMed ID: 29807374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A review on cardiovascular effects of newer hypoglycaemic medications.
    Cutshall BT; Twilla JD; Olinger AS; Oliphant CS
    Ann Med; 2017 Nov; 49(7):603-612. PubMed ID: 28540743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials.
    Giugliano D; De Nicola L; Maiorino MI; Bellastella G; Esposito K
    Diabetes Obes Metab; 2019 Aug; 21(8):1790-1800. PubMed ID: 30969018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lessons learned from cardiovascular outcome clinical trials with dipeptidyl peptidase 4 (DPP-4) inhibitors.
    Fiorentino TV; Sesti G
    Endocrine; 2016 Aug; 53(2):373-80. PubMed ID: 26611248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus.
    Asleh R; Sheikh-Ahmad M; Briasoulis A; Kushwaha SS
    Heart Fail Rev; 2018 May; 23(3):445-459. PubMed ID: 29270818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SAVOR-TIMI to DECLARE-TIMI: A Review on Cardiovascular Outcome Trials of Incretin-modulators and Gliflozins.
    Singh AK; Singh R
    Indian J Endocrinol Metab; 2019; 23(2):175-183. PubMed ID: 31161099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular safety of therapies for type 2 diabetes.
    Gupta P; White WB
    Expert Opin Drug Saf; 2017 Jan; 16(1):13-25. PubMed ID: 27652617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular outcome trials of glucose-lowering medications: an update.
    Home P
    Diabetologia; 2019 Mar; 62(3):357-369. PubMed ID: 30607467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel Anti-glycemic Drugs and Reduction of Cardiovascular Risk in Diabetes: Expectations Realized, Promises Unmet.
    Flory JH; Ukena JK; Floyd JS
    Curr Atheroscler Rep; 2016 Dec; 18(12):79. PubMed ID: 27817160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: a Review for the General Cardiologist.
    Patel KV; Sarraju A; Neeland IJ; McGuire DK
    Curr Cardiol Rep; 2020 Aug; 22(10):105. PubMed ID: 32770420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope.
    Giugliano D; Meier JJ; Esposito K
    Diabetes Obes Metab; 2019 May; 21(5):1081-1087. PubMed ID: 30609236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later.
    McGuire DK; Marx N; Johansen OE; Inzucchi SE; Rosenstock J; George JT
    Diabetes Obes Metab; 2019 May; 21(5):1073-1078. PubMed ID: 30690856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
    Paneni F; Lüscher TF
    Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Updates on cardiovascular outcome trials in diabetes.
    Schnell O; Rydén L; Standl E; Ceriello A;
    Cardiovasc Diabetol; 2017 Oct; 16(1):128. PubMed ID: 29020969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cardiovascular outcome clinical trials in type 2 diabetes mellitus: what are the epidemiological and methodological evidence and the first evaluations to date?].
    Fiorentino TV; Sesti G
    G Ital Cardiol (Rome); 2016 Mar; 17(3 Suppl 2):24S-31. PubMed ID: 27030121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Type 2 diabetes treatment and cardiovascular risk: what can we learn from trials?].
    Consoli A; Febo F
    G Ital Cardiol (Rome); 2016 Dec; 17(12 Suppl 2):20S-27. PubMed ID: 28151518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of Diabetes in Patients with Heart Failure.
    Bowes CD; Lien LF; Butler J
    Curr Cardiol Rep; 2018 Aug; 20(10):97. PubMed ID: 30151728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and Cardiovascular Outcomes: A Meta-analysis.
    Peterson SC; Barry AR
    Curr Diabetes Rev; 2018; 14(3):273-279. PubMed ID: 28413990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.